Table 11.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Heart Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		2,297	2,340	2,363	2,343	2,293	2,348	2,188	2,199	2,202	2,155
Tx with Antirejection Treatments		949	934	955	854	872	978	916	900	852	797
Antibodies	Category Usage	26.6%	22.7%	20.8%	18.1%	19.3%	21.3%	17.7%	16.3%	15.5%	17.6%
	ALG	0.4%	1.8%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	3.6%	7.7%	8.1%	5.4%	7.9%	7.3%	6.3%	4.6%	3.9%	4.0%
	OKT3	24.0%	16.7%	14.5%	13.9%	13.1%	14.9%	7.4%	5.1%	5.8%	6.9%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	2.0%	3.8%	4.9%	6.4%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.1%	0.8%	2.5%	3.0%	2.5%	1.5%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.9%	2.0%	0.4%	0.4%
Corticosteroids	Category Usage	88.1%	89.4%	92.6%	88.3%	88.6%	87.9%	91.3%	92.3%	92.7%	91.8%
	Steroids	88.1%	89.4%	92.6%	88.3%	88.6%	87.9%	91.3%	92.3%	92.7%	91.8%
Antimetabolites	Category Usage	12.5%	7.7%	6.6%	5.4%	7.6%	6.5%	4.6%	4.4%	2.0%	2.9%
	Cytoxan	2.0%	1.4%	1.8%	1.8%	3.6%	2.5%	2.1%	1.7%	0.5%	0.9%
	Methotrexate	10.5%	6.3%	4.9%	3.6%	4.1%	4.3%	2.6%	2.8%	1.5%	2.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.